NCI-designated Consortium Cancer Center
|
|
|
|
Hailey McDaniels, M.P.H., named Executive Director of Moores Cancer Center, Clinical Trials Office
Hailey McDaniels has been promoted to Executive Director of the Moores Cancer Center (MCC), Clinical Trials Office (CTO). Hailey oversees the 146-member team of the CTO, which serves over 100 investigators and manages 290 open clinical trials. Hailey joined MCC in December, 2014 and has grown and shaped the operation through many changes and opportunities. She partners with CTO Medical Director, Dr. Sandip Patel, to lead the largest component of MCC infrastructure. Congratulations Hailey, the promotion is well-deserved.
|
|
|
Biorepository and Tissue Technology Shared Resource
Thanks to the generous contribution of the Gleiberman Head and Neck Cancer Center, the Moores Cancer Center, Tissue Technology Shared Resource has recently purchased a Phenocycler-Fusion from AKOYA Biosciences. This technology will play a key role in immuno-oncology research by allowing the study of spatial interactions of tumor and immune cells.
The PhenoCycler™-Fusion allows spatial phenotyping of millions of cells at unprecedented scale and speed. Mapping millions of cells and their interactions in a single intact tissue section facilitates the discovery of rare cell types, cellular neighborhoods, and spatial functional states. Push the frontiers of spatial biology with your team using the PhenoCycler solutions (formerly CODEX®).
|
| |
Accepting Applications for Associate Director,
Diversity, Equity, and Inclusion
|
|
| |
Moores Cancer Center (MCC) is recruiting an Associate Director of Diversity, Equity, and Inclusion (DEI) to lead DEI initiatives that foster an inclusive and anti-racist environment for all members and employees of the MCC. The position has been established to support the National Cancer Institute’s commitment to ensure that (1) all Americans share equally in the medical advances that result from cancer research and (2) current disparities in the cancer burden are reduced or eliminated. As such, the position will provide strategic leadership, coordination, and implementation of DEI-related programs, initiatives, policies, and evaluative activities to enhance the diversity of MCC staff, faculty, students, and leadership.
For more information on this exciting opportunity, please visit the link below.
DEADLINE: July 31, 2022
MORE INFO
|
|
|
Accepting Applications for Vice Chair, Data and Safety Monitoring Committee (DSMC)
|
|
|
| Compensation
Effort: 5% up to NIH cap
Required Qualifications
Faculty member of UCSD, SDSU, or LJI with experience as a PI of a cancer clinical trial
Moores Cancer Center (MCC) Member
Experience as PI/Site PI of Phase I/II investigator-initiated trials
Preferred Qualifications
An ideal candidate would (1) have experience in both industry sponsored and investigator-initiated cancer therapeutics trials, (2) be detail oriented, and (3) be
committed to maintaining the integrity of clinical trials at MCC and executing the Data Safety and Monitoring Plan as written in the Cancer Center Support Grant
Time Commitment
2-4 hours per month for Committee meetings plus time to review material prior to meetings; more depending on level of involvement with other projects or potential of ad hoc reviews
Term
Recommended to be 3 years
DEADLINE EXTENDED TO JULY 31, 2022
MORE INFO
|
|
| |
DRM Seminar Series - “Immune and Stromal Interactions in the Regulation of Skeletal Muscle Disease”
Monday, August 8th, 2022
3:00 pm – 4:00 pm
Armando Villalta, PhD
Assistant Professor
Department of Physiology and Biophysics
University of California, Irvine (UCI)
Hosted by Rob Signer, PhD
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Saturday, July 23, 2022
9:00 a.m. - 10:00 a.m.
"Keeping Kids Healthy: HPV Vaccinations"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to present HPV vaccination information to the community.
Speakers:
Maya Kumar, M.D., UC San Diego Health
Mike West, J.D., HPV Cancer Survivor and Advocate
Andrew Gonzalez, Champions for Health
|
|
|
August 1–7: California HPV Vaccine Week
Look out for events and information on HPV vaccination learning opportunities! Partner Assemblymember Dr. Akilah Weber is introducing a resolution in the state assembly. Be sure to follow us on Twitter @UCSDCancer_COE for updates. More information to come!
MORE INFO
|
|
|
Saturday, August 13, 2022
10:00 a.m. - 1:00 p.m.
"Backpack Giveaway and HPV Vaccination Clinic"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to make HPV vaccinations available via our community partner Champions for Health. Cancer education also will be provided at the event.
Location: Lemon Grove Recreation Center
REGISTER HERE
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITY
|
|
|
2022 Pediatric Cancer Research – Special Grant Opportunity & Significantly Larger Awards V Scholar or Translational or All-Star
$600,000 - $1,000,00 (depending on mechanism)
PURPOSE OF AWARD: Due to exceptional fundraising levels in 2022, the VFoundation is offering an additional pediatric cancer research grant opportunity. This grant opportunity will be implemented through one of three grant mechanisms: VScholar, Translational, or All-Star grant types.
MCC Limited Submission LOIs must be submitted to Angela Ballantyne, Ph.D. by the internal deadline of Thursday, August 11, 2022 at 5:00 p.m.
|
|
|
NIH Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24)
Funding Available: $350,000
Funds are to modernize operations of existing research facilities through the purchase and installation of advanced equipment that enable and enhance a broad range of research-supporting activities. Supported equipment must be used substantially in a laboratory research core facility, animal facility, or similar shared-use research space to ensure broad benefits for the institutional research community. Requests must be justified by research-related demands for the modernization of research-supporting functions or for the advancement of facility operations. Equipment must benefit the larger biomedical research enterprise at the applicant institution and represent a technological step forward.
Internal Limited Submission Deadline: Tuesday, August 9, 2022 at 5:00 p.m. (one submission per institution)
Funding Organization's Deadline: Monday, November 7, 2022
MORE INFO
|
|
|
HHMI Freeman Hrabowski Scholars Program
Awards will cover full salary, benefits, and a research budget of approximately $2M direct for 5 years
This new program will support outstanding basic researchers and physician-scientists who exhibit the strong potential to become leaders in their fields and advance diversity, equity, and inclusion. Eligible research areas include not only all basic biomedical science disciplines, but also plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering, and computational biology. Applicants must have begun a tenure-track faculty position on or after July 1, 2018 or have accepted an offer for a position that will begin no later than July 1, 2023. Up to 30 awards will be made in 2023; future competitions are anticipated every other year. Watch the recording of an information session.
Applications due: September 28, 2022
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Susan G. Komen Career Catalyst Research (CCR) Grants for Early Career Investigators
Funding Level: Up to $450,000 over 3 years ($150,000 per year, combined direct and indirect costs)
Through this grant mechanism, we seek to support emerging leaders of the next generation of researchers engaged in the quest to end breast cancer.
Research Focus Areas: CCR Grants will support outstanding research focused on two important aspects of precision medicine: the development of next generation-targeted therapies and the development of interventions to eliminate breast cancer health disparities. Proposals that are basic, translational, clinical, or population science focused and address at least one focus area listed below will be considered.
Beyond PARP Inhibitors: Next-generation breast cancer therapies that target the genome and epigenome
Beyond T-Cells: Next generation breast cancer immunotherapy
Closing the Gap: New approaches to address multi-level contributors to breast cancer disparities
Letters of Intent Deadline Is Extended to August 1, 2022, 1:00 p.m. EST
Full Application Due: October 5, 2022 by 1:00 p.m. EST
MORE INFO
|
|
|
DOD Breast Cancer Research Program: Transformative Breast Cancer Consortium Award
$25M direct for up to 4 years
The U.S. Department of Defense, Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will (1) transform the lives of individuals with, and/or at risk for, breast cancer and (2) accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
Pre-Application Deadline: August 8, 2022
MORE INFO
|
Damon Runyon Cancer Research Foundation Fellowship Award
$60,000 - $66,000 in stipend support for four years plus additional educational or scientific expenses and a child dependent allowance
The Damon Runyon Cancer Research Foundation is a leading nonprofit organization that funds brave and bold young cancer researchers.
Damon Runyon views cancer research very broadly: not only the full spectrum of basic questions important to normal human biology and carcinogenesis, but also the development of new platforms and technologies. We encourage all theoretical and experimental research with the potential to provide insight about cancer and the search for cancer causes, mechanisms, therapies, and prevention, for all types of cancer.
Application Deadline: August 15, 2022
MORE INFO
|
NCCN, Pfizer, and EMD Serono Quality of Care Initiative to Improve the Treatment of Locally Advanced or Metastatic Bladder Cancer Patients
The intent of this RFP is to fund individual projects capped at $150,000 (direct
and indirect costs) although smaller, lower-costs projects are
encouraged. Funding greater than $150,000 will be considered for
exceptional proposals with detailed budget justification.
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (GMG) and EMD Serono to offer a second grant opportunity to support quality improvement projects that will advance the quality of care and include guideline concordant care, and best practices around treatment for patients with locally advanced or metastatic disease (Stage IV, according to the AJCC TNM staging system) bladder cancers.
The intent of the RFP also is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit proposals that describe concepts and ideas around how to improve the quality of care, which include guideline concordant care and best practices for treating patients with locally advanced or metastatic disease bladder cancers.
Submit Proposal by Thursday, August 18, 2022 by 5:00 p.m. ET
MORE INFO
|
2022 Moores Cancer Center Community Outreach & Engagement (COE)
Pilot Project Awards to Stimulate Research in Catchment Area Priority Cancers Request for Proposals (RFP)
PURPOSE: Moores Cancer Center Community Outreach and Engagement (COE) invites full and associate members, post-docs with an established member mentor, and early-stage investigators from the MCC consortium (UC San Diego, San Diego State University, La Jolla Institute for Immunology) to submit proposals for pilot awards to support catchment area priority cancer research. Expected return on investment is a successful K-series, R-series, or other similar extramural award as a result of preliminary data generated by pilot award support.
Submissions are required to address one or more catchment area (San Diego County) priority cancers: lung, breast, prostate, colorectal, pancreas, liver, leukemia, and HPV-driven cancers.
2022 COE PILOT AWARD FUNDS AVAILABLE:
- One (1) award up to $50K total costs/year for one (1) year is expected to be funded
- A PI or co-PI may submit only one application
- Funds are subject to availability
View the COE Pilot RFA Informational Webinar Recording Here
View Webinar Slides Here
Deadline: August 19, 2022 @5:00 PM (PST)
MORE INFO
|
Hanna and Mark Gleiberman Head and Neck Cancer Center, Request for Applications (RFA) Research Pilot Project Grant Opportunity
PURPOSE: The UC San Diego Health, Gleiberman Head and Neck Cancer Center is dedicated to providing support for the care of patients with head and neck cancer and their families. The Center strives to not only provide effective, state-of-the-science head and neck cancer care, but also develop innovative, evidence-based approaches that facilitate novel therapies for head and neck cancer and a productive and healthy life for patients and their families.
The Gleiberman Head and Neck Cancer Center is seeking applications for pilot project grants under the Gleiberman Head and Neck Cancer Center Pilot Project Grant Award Program that will ultimately improve curative therapy and the quality of care for head and neck cancer patients and their families. Research proposals may address any aspect of head and neck cancer care or head and neck and/or voice disease etiology, diagnosis, therapy.
The Gleiberman Head and Neck Cancer Center is particularly interested in applications from investigators who have not been involved in translational head and neck cancer research, but whose fundamental research, possibly involving but not limited to cancer mechanisms or technology development, may be newly applied to head and neck cancer. Applications from junior investigators also are strongly encouraged.
Proposals may be submitted for either a 1- or 2-year grant period. Up to $75,000 of direct costs per year may be requested, with the second year of funding contingent upon progress during the first year. Indirect costs are not allowed. Travel and equipment costs are not allowed.
Deadline: August 24, 2022 by 5:00 p.m. PST
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to (1) promote new cancer disparities research among investigators who do not normally conduct it and (2) encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to, basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved populations.
Deadline: September 6, 2022
|
Melanoma Funding Opportunity
Melanoma Research Alliance and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) will offer two informational webinars next week to overview our recently announced Special Opportunity RFP for Team Science Awards focused on patient-centric clinical trials.
Webinar One - July 26 at 9:00 a.m. ET - Register Here
Webinar Two - July 28 at 11:00 p.m. ET - Register Here
Two team awards. $1,500,000/each
Deadline: October 5, 2022
MORE INFO
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI's Informatics Technology for Cancer Research (ITCR) Program targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
Melanoma Research Alliance (MRA) RFP for Team Science Awards that target patient-centric clinical trials, jointly funded by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA
$1.5 million
These awards will fund clinical trials with the potential to provide significant benefit to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.
Letters of Intent due 11:59 p.m. ET, October 5, 2022
Estimated LOI decisions: November 18, 2022
Invited Full Proposals due 11:59 p.m. ET, January 18, 2023
|
|
|
|
Tuesday, October 11, 2022
UC San Diego, Moores Cancer Center
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
|
|
|
Thursday to Friday, October 20-21, 2022
Time: TBD
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center, Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
- Recent breakthroughs in regenerative medicine
-
Stem cell regeneration in several disease areas
- Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Hosted by
Catriona Jamieson, M.D., Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center, and Chief of the Division of Regenerative Medicine and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Keynote Speakers
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
MORE INFO
|
Tuesday to Saturday, November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting and Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
REGISTER TODAY!
|
Saturday, January 28, 2023
Prostate Cancer Patient Summit
More information to come!
|
|
|
Newly Opened Clinical Trials (June, 2022)
|
|
|
New Hires in the CTO
Christina Lugo (7/11) - Experimental Therapeutics Clinical Research Coordinator
Nicole Daniel (7/11) - Gyn Onc Clinical Research Coordinator
Lissa Pereira (7/18) - Experimental Therapeutics Clinical Research Coordinator
Dana Hamilton (7/18) - Breast Team Clinical Research Coordinator
| |
|
Rios-Covian, D., Butcher, L. D., Ablack, A. L., den Hartog, G., Mastsubara, M. T., Ly, H., Oates, A. W., Xu, G., Fisch, K. M., Ahrens, E. T., Toden, S., Brown, C. C., Kim, K., Le, D., Eckmann, L., Dhar, B., Izumi, T., Ernst, P. B., & Crowe, S. E. (2022). A novel hypomorphic Apex1 mouse model implicates apurinic-apyrimidinic endonuclease 1 in oxidative DNA damage repair in gastric epithelial cells. Antioxidants & redox signaling, 10.1089/ars.2021.0119. Advance online publication.
Pierce, J. P., Zhang, J., Crotty Alexander, L. E., Leas, E. C., Kealey, S., White, M. M., Strong, D. R., Trinidad, D. R., McMenamin, S. B., Chen, R., Benmarhnia, T., & Messer, K. (2022). Daily E-cigarette Use and the Surge in JUUL Sales: 2017-2019. Pediatrics, e2021055379. Advance online publication.
Seymour, J. F., Kipps, T. J., Eichhorst, B., D'Rozario, J., Owen, C., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, Q. J., Jiang, Y., Lefebure, M., Boyer, M., Kater, A. P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, blood.2021015014. Advance online publication.
|
|
|
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center
OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both MDs and PhDs and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The focus of the research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or industrial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure
See website for more details about CT2 program: WEBSITE
Complete CT2 program application (form available to download from the website above)
Curriculum Vitae
One-page personal statement
Proof of U.S. Citizenship/Residency
Three letters of recommendation (one from an identified mentor)
Skills and Knowledge Required: PhD or MD degree, U.S. Citizen or permanent resident status
For more information or to apply, please contact
Amy Spilkin, Ph.D.
Deadline: October 15, 2022
|
- RA2, Post Award (candidates hired into this position can work remotely, in-person or hybrid). Req #117071
-
RA3 or RA2, Pre-Award (candidates hired into this position can work remotely, in-person or hybrid). – Req #117444
-
Financial Analyst 1 – Req #116694
- Financial Analyst 2 – Req #117186
-
Contracts and Grants Supervisor- Req #117223
- Research and Grant Writer – Req #116068
|
|
|
If you have newsworthy items to contribute, then please contact our Marketing & Communications Manager, Renee Maude at amaude@health.ucsd.edu.
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded in 1978, the same year it received its NCI designation.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
